Pilatus Biosciences' PLT012 Receives Orphan Drug Designation for Liver and Intrahepatic Bile Duct Cancer

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT0...

December 11, 2024 | Wednesday | News
Arvinas and Pfizer Report Promising Preliminary Data for Vepdegestrant and Abemaciclib Combo in ER+/HER2- Breast Cancer

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdege...

December 11, 2024 | Wednesday | News
Merck's KEYTRUDA® Combined with LYNPARZA® Achieves Key Milestone in Phase 3 Trial for Advanced Ovarian Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA ® (...

December 10, 2024 | Tuesday | News
Amgen’s BLINCYTO® Significantly Improves Disease-Free Survival in Pediatric B-ALL, Redefining Standard of Care

Amgen (NASDAQ:AMGN) announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease...

December 09, 2024 | Monday | News
Pfizer to Showcase Latest Hematology and Breast Cancer Advancements at ASH and SABCS 2024

Pfizer Inc. (NYSE: PFE) will highlight the latest advancements from its growing hematology and breast cancer portfolios at the American Society of Hematolo...

December 09, 2024 | Monday | News
Thermo Fisher Launches Innovative CTS™ Detachable Dynabeads™ to Redefine T Cell Therapy Manufacturing

T cell isolation and controlled release delivers flexibility and control in process development, clinical trials and commercial manufacturing  Ther...

December 05, 2024 | Thursday | News
Duality Biologics Signs Exclusive Option Agreement with GSK for ADC Candidate DB-1324 in Gastrointestinal Cancer

 Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjuga...

December 04, 2024 | Wednesday | News
LG AI Research Leverages AWS to Accelerate Cancer Diagnosis with EXAONEPath Pathology Model

At AWS re:Invent, Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN),  announced that LG AI Research, the artificial intelligence (...

December 04, 2024 | Wednesday | News
Beyond Cancer Receives Israeli Ministry of Health Approval for Phase 1b Trial of LV UNO in Combination with Anti-PD-1 Therapy

Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors...

December 04, 2024 | Wednesday | News
Gilead Sciences Partners with Tubulis to Develop Next-Generation Antibody-Drug Conjugate for Solid Tumors

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover...

December 04, 2024 | Wednesday | News
Kelun-Biotech's Sacituzumab Tirumotecan (Sac-TMT) Gains Marketing Approval for Advanced TNBC in China

The competition among three TROP2 antibody-drug conjugates is entering a new stage as Kelun-Biotech’s Merck & Co.-partnered sacituzumab...

December 02, 2024 | Monday | News
Aulos Bioscience Doses First Patient in Phase 2 Trial for Second-Line PD-L1+ NSCLC Treatment

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, tod...

November 29, 2024 | Friday | News
European Commission Approves TEVIMBRA® for First-Line Treatment of Esophageal and Gastric Cancers

 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, announced ...

November 28, 2024 | Thursday | News
Novartis Announces European Commission Approval of Kisqali® (ribociclib) for Adjuvant Treatment of High-Risk HR+/HER2- Early Breast Cancer

Novartis announced that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the ad...

November 28, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close